Gigengack, Norman K.
Oertel, Frederike C.
Motamedi, Seyedamirhosein
Bereuter, Charlotte
Duchow, Ankelien
Rust, Rebekka
Bellmann-Strobl, Judith
Ruprecht, Klemens
Schmitz-Hübsch, Tanja
Paul, Friedemann
Brandt, Alexander U.
Zimmermann, Hanna G.
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 14 January 2022
Accepted: 6 September 2022
First Online: 20 October 2022
Competing interests
: FO was an employee of Nocturne UG (2018) and recieved research support by American Academy of Neurology (2021–2023), National Multiple Sclerosis Society (2021–2024) and Deutsche Gesellschaft für Neurologie (2021)—all independent from this project. KR received research support from Novartis Pharma, Merck Serono, German Ministry of Education and Research, European Union (821283-2), Stiftung Charité (BIH Clinical Fellow Program) and Arthur Arnstein Foundation; received travel grants from Guthy Jackson Charitable Foundation.J. Bellmann-Strobl has received speaking honoraria and travel grants from Bayer Healthcare, and sanofi-aventis/Genzyme, in addition received compensation for serving on a scientific advisory board of Roche, unrelated to the presented work. F. Paul served on the scientific advisory boards of Novartis and MedImmune; received travel funding and/or speaker honoraria from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an associate editor of Neurology: Neuroimmunology & Neuroinflammation; is an academic editor of PLoS ONE; consulted for Sanofi Genzyme, Biogen, MedImmune, Shire, and Alexion; received research support from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis/Geynzme, Alexion, and Merck Serono; and received research support from the German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy-Jackson Charitable Foundation, and NMSS. AUB is cofounder and shareholder of medical technology companies Nocturne GmbH and Motognosis GmbH. He is named as inventor on several patent applications describing MS biomarkers, visual perceptive computing based motor function analysis, and retinal image analysis. H.G. Zimmermann received research grants from Novartis and speaking honoraria from Bayer Healthcare and Novartis.The other authors report no competing interests.